Medincell SA is a renowned pharmaceutical company committed to innovation and research. With a strong focus on improving patients' lives, Medincell SA values integrity, excellence, and collaboration. The company's corporate philosophy revolves around delivering advanced drug delivery solutions and enhancing therapies. Medincell SA strives to develop partnerships and build a global network to accelerate the development and commercialization of its proprietary products. By integrating technology, science, and patient needs, Medincell SA aims to revolutionize drug delivery, offering sustainable and patient-centric solutions. Through its unwavering dedication to innovation and patient care, Medincell SA sets itself apart in the pharmaceutical industry.

Medincell SA is primarily present in France and the United States.

Medincell SA has attained several notable milestones. Its most significant achievements include successful clinical trials for their long-acting injectable formulations, regulatory approvals for key products, and collaborations with reputed pharmaceutical companies. Notably, the company secured FDA approval for a long-acting antipsychotic treatment, MedinCell's Atrigenic, marking a significant milestone in the field of mental health therapeutics. Additionally, Medincell SA forged strategic partnerships with renowned pharmaceutical giants, enabling them to expand their reach and leverage their innovative drug delivery technologies. With these achievements, Medincell SA has established itself as a pioneering force in the pharmaceutical industry, driving advancements in long-acting drug formulations.

Medincell SA is a pharmaceutical company specializing in controlled release drug delivery technologies. Founded in 2011, Medincell focuses on developing innovative therapeutic products to enhance treatment efficacy and patient adherence. The company is headquartered in Jacou, France, and operates with a team of experienced professionals dedicated to improving drug delivery systems. Medincell SA aims to revolutionize the pharmaceutical industry by offering sustained drug release solutions that provide targeted and continuous therapeutic effects. With a commitment to scientific excellence and advanced technologies, Medincell SA continues to make significant strides in the field of controlled release drug delivery.

The main competitors of Medincell SA in the market include pharmaceutical companies such as GlaxoSmithKline, Novartis, and Johnson & Johnson. These companies also specialize in developing and manufacturing innovative drug delivery technologies and products. Medincell SA faces competition in the market due to the constant need for advancements and solutions in the pharmaceutical industry.

Medincell SA is primarily active in the pharmaceutical industry.

Medincell SA is a pharmaceutical company focusing on the development of long-acting injectable drug delivery systems. Their business model revolves around pioneering technology to create innovative products for controlled release of medicines. Medincell SA aims to enhance patient care by offering sustained-release formulations, providing a more convenient and effective treatment option. By leveraging their proprietary BEPO technology, Medincell SA aims to address therapeutic challenges and optimize drug delivery to improve clinical outcomes. With a dedication to research and development, Medincell SA aims to revolutionize the pharmaceutical industry and contribute to the advancement of patient healthcare.

Medincell의 P/E 비율은 -17.3입니다.

Medincell의 P/S 비율은 47.95입니다.

Medincell에 대한 AlleAktien 품질 점수는 4/10입니다.

Medincell 매출은 9.03 백만 EUR입니다.

Medincell 이익은 -25.04 백만 EUR입니다.

Medincell SA is a pharmaceutical company based in France that specializes in the development and marketing of long-acting drugs. The company is known for its groundbreaking technologies that allow for the release of medications into the body, resulting in a duration of up to three months. Medincell focuses on developing drugs for chronic diseases that require regular, long-term treatment. The company is composed of several business units that focus on different aspects of drug development and marketing. The research and development area is the core of Medincell, where the company develops its groundbreaking technologies and drug formulations. Medincell has a pipeline of projects aimed at developing long-acting drugs for use in chronic diseases. Another key area of Medincell is the manufacturing and marketing of its products. The company will not sell its products directly to end consumers, but rather to pharmaceutical companies, hospitals, or medical practices that will then prescribe them to patients. This allows Medincell to focus on developing high-quality, patient-oriented products without having to worry about direct marketing and distribution. Another important business area for Medincell is collaboration and partnerships with other pharmaceutical companies. Medincell has entered into a strategic partnership with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, to develop a novel long-acting antipsychotic. In addition, the company has also entered into a collaboration with Pharmaserv Alliance to market its products in the United Arab Emirates and Saudi Arabia. Medincell is also advancing the development of its technology platform. The company is working on developing new release technologies for various types of drugs, including DNA-based therapeutics and cancer drugs. These technologies are intended to make medications even more effective and safer. In addition to the development and marketing of long-acting drugs, Medincell is also working on other solutions for the healthcare industry. These include innovative technologies for the administration of diabetes medications or the treatment of chronic pain. Overall, Medincell SA has an impressive and promising business strategy for the field of long-acting drug development. With innovative technologies, forward-thinking partnerships, and a clear focus on the needs of patients, the company expects to be successful in the future.

Medincell은(는) 연간 번의 배당을 통해 0 EUR의 배당금을 지급합니다.

Medincell의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Medincell의 ISIN은 FR0004065605입니다.

Medincell의 WKN은 A2N6VA입니다.

Medincell의 티커는 MEDCL.PA입니다.

지난 12개월 동안 Medincell은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Medincell은(는) 0 EUR의 배당금을 지급할 것으로 예상됩니다.

Medincell의 현재 배당 수익률은 입니다.

Medincell은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Medincell은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 EUR의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Medincell은 '건강' 섹터에 속합니다.

Medincell의 마지막 배당금을 0 EUR만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Medincell는 0 EUR를 배당금으로 지급했습니다.

Medincell의 배당금은 EUR에 지급됩니다.